

# Molecular Mechanisms of Insulin Resistance

## Interactions with adipose tissue's molecules

Júlia Pié Orpí – Treball de Fi de Grau

### INTRODUCTION

Insulin resistance is the cell's incapacity to respond to the normal actions of the hormone that leads to a decrease in cell survival, glucose uptake and the synthesis of protein, glycogen and fatty acids. Insulin exerts its immediate effects via the activation of the **IR/IRS/PI3K/PKB signaling pathway**. Molecules related with the adipose tissue can modulate this pathway, increasing or decreasing insulin sensitivity. Some of these molecules are **adiponectin**, **leptin**, **resistin** and inflammatory factors such as **tumor necrosis factor alpha (TNF- $\alpha$ )** and **interleukine 6 (IL-6)**.

### Adiponectin

It **increases fatty acid oxidation** and **improves insulin sensitivity**.

**Targets:** AMPK and PPAR.

**Activates:** TSC and fatty acid transporters.  
**Reduces:** mTORC, ACC, IKK, SREBP and ChREBP.

**Increases** glucose uptake via GLUT 4 translocation. **Reduces** gluconeogenesis by blocking PEPCK and G6P.

↓ insulin resistance

### Leptin

It **decreases hunger**, **thermogenesis** and **fatty acid oxidation**.

**Leptin resistance State:** hormone levels are high but cells don't respond to it. It appears in obese patients.

**Caused by:** BBB transport deficiency AND SOCS3 activation: inhibits JAK/STAT leptin signaling pathway.

**Increases** lipogenesis (c-fos and SREBP activation).

↑ insulin resistance

### Antidiabetic Drugs

#### Biguanides

Metformin is the most used biguanide.

**Targets:** AMPK and PPAR → fatty acid oxidation increase/ lipogenesis block.

**Insulin sensitivity increase:** ↑ peripheral glucose and glucose uptake  
↓ hepatic glucose production.


#### Thiazolidinediones (TZDs)

**Targets:** AMPK and PPAR $\gamma$

**Insulin sensitivity increase:** ↑ glucose use for energy expenditure  
inflammatory cytokines block

### CONCLUSIONS

Adipose tissue's related molecules modulate insulin resistance, promoting this pathology in overweight status. Insulin resistance can also be seen in **veterinary medicine**, with a lower prevalence, mostly related with an animal's **inadequate nutrition** or **life style** that lead to obesity. Two antidiabetic drugs broadly used, **Metformin** and **TZDs**, have the same targets: **AMPK** and **PPAR**, making clear that both molecules have a **crucial role** in insulin resistance. There is a **need for further research** since many of the **mechanisms** involved in this pathology remain **incompletely understood** and the **perspectives** of finding **new drugs** are favorable.



### TNF- $\alpha$ & IL-6

**Cytokines** mostly produced by **macrophages**. Higher expression in obesity (systemic inflammatory state).

#### IL-6

**Activates:** SOCS3, MAPKs and PKC.

#### TNF- $\alpha$ :

**Activates:** IKK → NF- $\kappa$ B, S6K, JNK1.

**Inhibits:** GLUT 4, ACS, JNK and perilipin.

**Increases** cytokine production and expression and lipid accumulation.

**Modulates** gene expression.

↑ insulin resistance

### Resistin

It recruits **proinflammatory factors** and **immune cells**. It's mostly produced by **monocytes** and **macrophages**.

**Decreases:** AMPK, PPAR, PKB activity, ROR activation and Foxo1 expression.

**Activates:** GSK3, ERK1/2 and SOCS3.

**Increases** gluconeogenesis and lipogenesis.

Human relevance not proved.

↑ insulin resistance




Fig. PPAR multiple roles (Ahmadian, M. et al., 2013).

**ABBREVIATIONS:** Insulin receptor (IR); insulin receptor substrates (IRS); phosphoinositide-dependent kinase-1 (PDK1); protein kinase B (PKB); AMP-activated protein kinase (AMPK); peroxisome proliferator-activated receptors (PPAR); tuberous sclerosis complex (TSC); mammalian target of rapamycin complex 1&2 (mTORC1/2); acetyl Co-A carboxylase (ACC); I $\kappa$ B kinase (IKK); sterol regulatory element-binding protein (SREBP); carbohydrate-responsive element-binding protein (ChREBP); phosphoenolpyruvate carboxykinase (PEPCK); glucose 6-phosphatase (G6P); blood-brain barrier (BBB); suppressor of cytokine signaling 3 (SOCS3); janus-kinase/signal transducers and activators of transcription (JAK/STAT); mitogen-activated protein kinase (MAPKs); protein kinase C (PKC); nuclear factor- $\kappa$ B (NF- $\kappa$ B); c-Jun N-terminal kinases (JNK); glycogen synthase kinase 3 (GSK3); extracellular signal-regulated kinases 1&2 (ERK1/2); tyrosine-protein kinase transmembrane receptor (ROR).



UAB  
Universitat Autònoma  
de Barcelona